The invention relates to the identification and generation of antibodies that specifically bind to SLC15A2 protein. The disclosed anti-SLC15A2 antibodies and compositions comprising them may be used for diagnosis, prognosis and therapy of cancer (including metastatic cancer) or fibrotic conditions, e.g., ovarian cancer, cervical cancer, prostate cancer, uterine cancer, lung cancer, lung fibrosis, and glioblastoma. The disclosed antibodies include conjugates with cytotoxic effector components that are useful for cancer therapy.